Cargando…

P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)

Detalles Bibliográficos
Autores principales:	Ludwig, Heinz, Melchardt, Thomas, Sormann, Siegfried, Schreder, Martin, Andel, Johannes, Hartmann, Bernd, Tinchon, Christoph, Zojer, Niklas, Gunsilius, Eberhard, Podar, Klaus, Egle, Alexander, Willenbacher, Wolfgang, Woell, Ewald, Ruckser, Reinhard, Bozic, Boris, Theresa Krauth, Maria, Petzer, Andreas, Schmitt, Clemens A., Machherndl-Spandl, Sigrid, Agis, Hermine, Fillitz, Michael, Wang, Song-Yau, Knop, Stefan, Paiva, Bruno, Greil, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431585/ http://dx.doi.org/10.1097/01.HS9.0000970676.55498.d5

Ejemplares similares

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group
por: Leisch, Michael, et al.
Publicado: (2022)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
por: Ludwig, Heinz, et al.
Publicado: (2020)

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

Mechanisms and Materials for NTE
por: Attfield, J. Paul
Publicado: (2018)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT
por: Pleyer, Lisa, et al.
Publicado: (2023)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021)

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2021)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Discovery of a rapidly evolving yeast defense factor, KTD1, against the secreted killer toxin K28
por: Andreev, Ilya, et al.
Publicado: (2023)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

CoNTe: A Core Network Temporal Blockchain for 5G
por: Platt, Steven, et al.
Publicado: (2020)

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
por: Gampenrieder, S.P., et al.
Publicado: (2022)

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
por: Egle, Alexander, et al.
Publicado: (2019)

943. Epidemiology of Actinomycosis in a Tertiary Care Cancer Center
por: El-Atoum, Mohammad, et al.
Publicado: (2021)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
por: Pleyer, Lisa, et al.
Publicado: (2017)

Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group
por: Jansko-Gadermeir, Bettina, et al.
Publicado: (2023)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
por: Byun, Ja Min, et al.
Publicado: (2020)

PB2134: BCMA-TARGETED THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A SINGLE CENTER EXPERIENCE
por: Strassl, Irene, et al.
Publicado: (2023)

Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN)()
por: Richardson, Rudy J., et al.
Publicado: (2020)

PNPLA6/NTE, an Evolutionary Conserved Phospholipase Linked to a Group of Complex Human Diseases
por: Kretzschmar, Doris
Publicado: (2022)

No Time for Rest: An Exploration of Sleep and Social Harm in the North East Night-Time Economy (NTE)
por: Bushell, Mark G.
Publicado: (2022)

S174: MYELOID NGS ANALYSES OF PAIRED SAMPLES FROM BONE MARROW AND PERIPHERAL BLOOD YIELD CONCORDANT RESULTS: A PROSPECTIVE COHORT ANALYSIS OF THE AGMT STUDY GROUP
por: Pleyer, Lisa, et al.
Publicado: (2023)

The Novel Effector Ue943 Is Essential for Host Plant Colonization by Ustilago esculenta
por: Wang, Shuqing, et al.
Publicado: (2023)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Organophosphate-Induced Changes in the PKA Regulatory Function of Swiss Cheese/NTE Lead to Behavioral Deficits and Neurodegeneration
por: Wentzell, Jill S., et al.
Publicado: (2014)

Genome sequence of the clover-nodulating Rhizobium leguminosarum bv. trifolii strain SRDI943.
por: Reeve, Wayne, et al.
Publicado: (2013)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

943 Prospective evaluation of a cluster of Pseudomonas aeruginosa isolates identified by automated statistical software
por: Cloonan, Sean, et al.
Publicado: (2014)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Delayed Induction of Human NTE (PNPLA6) Rescues Neurodegeneration and Mobility Defects of Drosophila swiss cheese (sws) Mutants
por: Sujkowski, Alyson, et al.
Publicado: (2015)

Glial expression of Swiss cheese (SWS), the Drosophila orthologue of neuropathy target esterase (NTE), is required for neuronal ensheathment and function
por: Dutta, Sudeshna, et al.
Publicado: (2016)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

POS-943 ADHERENCE TO THE TREATMENT OF TRANSPLANTED PATIENTS FROM A PHI IN BARRANQUILLA IN TIMES OF THE COVID-19
por: Peña Arevalo, Z., et al.
Publicado: (2022)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Prevalence of the NTE(KPC)-I on IncF Plasmids Among Hypervirulent Klebsiella pneumoniae Isolates in Jiangxi Province, South China
por: Huang, Qi-Sen, et al.
Publicado: (2021)

TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer
por: Strassl, Irene, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1dv87sornhrb0kgj61skv0q6uv